We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Drug Development Doesn’t Always Have to Start From Scratch

Article   Jun 05, 2017 | Simon Pearce, Market Segment Manager for Organics, with Thermo Fisher Scientific

 
Drug Development Doesn’t Always Have to Start From Scratch
 
 
 

RELATED ARTICLES

Why does Ketamine Fight Depression? Finding Answers at BNA 2019

Article

A significant minority of major depressive disorder patients don’t respond to currently available antidepressant medication. A newly approved treatment, based on the "club drug" ketamine, could change that. In a session at the British Neuroscience Association’s Festival of Neuroscience 2019, the potential mechanisms of ketamine’s antidepressant action were put under examination.

READ MORE

The Evolving Field of Cancer Biomarkers

Article

Given the complexity of cancer, it’s arguably unlikely that single molecules will work as clinically meaningful biomarkers for cancer. Today, biomarker discovery involves detecting patterns – characteristics or phenotypes that can be measured and monitored throughout a patient’s journey. Here, we look at two approaches being explored in this evolving field.

READ MORE

Sensitivity vs Specificity

Article

When developing diagnostic tests or evaluating results, it is important to understand how reliable those tests and therefore the results you are obtaining are. By using samples of known disease status, values such as sensitivity and specificity can be calculated that allow you to evaluate just that.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE